| scholarly article | Q13442814 |
| P50 | author | Leila Akkari | Q55459044 |
| Johanna A Joyce | Q88589738 | ||
| Jason T Huse | Q88685699 | ||
| Eric C Holland | Q89747805 | ||
| Daniela F Quail | Q91215616 | ||
| Robert L Bowman | Q101051385 | ||
| Marsha L Quick | Q116996859 | ||
| Alberto J Schuhmacher | Q42574187 | ||
| P2093 | author name string | James C Sutton | |
| P2860 | cites work | Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles | Q24536351 |
| Exploring the full spectrum of macrophage activation | Q24653754 | ||
| The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo | Q24657924 | ||
| The 2007 WHO classification of tumours of the central nervous system | Q24685772 | ||
| DAVID: Database for Annotation, Visualization, and Integrated Discovery | Q27499374 | ||
| Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy | Q27690653 | ||
| Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor | Q27701677 | ||
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| The Sequence Alignment/Map format and SAMtools | Q27860966 | ||
| Regeneration beyond the glial scar | Q28239915 | ||
| The somatic genomic landscape of glioblastoma | Q28300185 | ||
| Characteristics of the alternative phenotype of microglia/macrophages and its modulation in experimental gliomas | Q28476714 | ||
| The insulin-like growth factor 1 receptor is essential for axonal regeneration in adult central nervous system neurons | Q28577192 | ||
| The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies | Q29614311 | ||
| Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm | Q29614349 | ||
| HTSeq--a Python framework to work with high-throughput sequencing data | Q29614489 | ||
| Regularization Paths for Generalized Linear Models via Coordinate Descent | Q29614491 | ||
| STAR: ultrafast universal RNA-seq aligner | Q29615052 | ||
| Microenvironmental regulation of tumor progression and metastasis | Q29615504 | ||
| Cancer drug resistance: an evolving paradigm | Q29616694 | ||
| Influence of tumour micro-environment heterogeneity on therapeutic response | Q29617534 | ||
| Insulin and insulin-like growth factor signalling in neoplasia | Q29619495 | ||
| Strengths and limitations of the neurosphere culture system | Q30054535 | ||
| GSVA: gene set variation analysis for microarray and RNA-seq data. | Q30586230 | ||
| TCGA-assembler: open-source software for retrieving and processing TCGA data | Q30827501 | ||
| Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia | Q33470265 | ||
| Germinal center B cells constitute a predominant physiological source of IL-4: implication for Th2 development in vivo | Q44723060 | ||
| A novel STAT6 inhibitor AS1517499 ameliorates antigen-induced bronchial hypercontractility in mice | Q46129015 | ||
| Latent enhancers activated by stimulation in differentiated cells | Q46305342 | ||
| FK506 controls CD40L-induced systemic autoimmunity in mice | Q46937604 | ||
| Loss of Arf causes tumor progression of PDGFB-induced oligodendroglioma | Q48200427 | ||
| Therapeutic targeting of tumor-associated macrophages and microglia in glioblastoma | Q48650505 | ||
| Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. | Q51659718 | ||
| Role of the INK4a locus in tumor suppression and cell mortality. | Q53455197 | ||
| Reciprocal regulation of polarized cytokine production by effector B and T cells | Q73256871 | ||
| Induction of macrophage insulin-like growth factor-I expression by the Th2 cytokines IL-4 and IL-13 | Q79074366 | ||
| Primary oligodendrocyte death does not elicit anti-CNS immunity | Q83515899 | ||
| ISMARA: automated modeling of genomic signals as a democracy of regulatory motifs | Q33564556 | ||
| voom: Precision weights unlock linear model analysis tools for RNA-seq read counts | Q33741687 | ||
| Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma | Q34083282 | ||
| NFAT pulls the strings during CD4+ T helper cell effector functions | Q34095005 | ||
| Insulin-like growth factor-1 (IGF-1): a neuroprotective trophic factor acting via the Akt kinase pathway. | Q34155161 | ||
| Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor | Q34172489 | ||
| Selective inhibition of calcineurin-NFAT signaling by blocking protein-protein interaction with small organic molecules | Q34335785 | ||
| Activation of microglia by aggregated beta-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-gamma and IL-4 render them protective. | Q34418439 | ||
| The Molecular Signatures Database (MSigDB) hallmark gene set collection | Q34509167 | ||
| CSF-1R inhibition alters macrophage polarization and blocks glioma progression | Q34993852 | ||
| PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo | Q35080265 | ||
| Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response | Q35779256 | ||
| Regulatory roles for cytokine-producing B cells in infection and autoimmune disease | Q35963652 | ||
| Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling | Q35973252 | ||
| Inferring transcriptional and microRNA-mediated regulatory programs in glioblastoma | Q36213745 | ||
| Transforming growth factor-beta and wound healing. | Q36455371 | ||
| Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study | Q36705917 | ||
| Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas | Q37281335 | ||
| Colony-stimulating factor-1 receptor inhibitors for the treatment of cancer and inflammatory disease | Q37581853 | ||
| Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system | Q37583027 | ||
| Epithelial stem cells, wound healing and cancer | Q37987841 | ||
| The many faces of insulin-like peptide signalling in the brain | Q37994953 | ||
| Macrophage plasticity and polarization in tissue repair and remodelling | Q38055370 | ||
| Reactive gliosis and the multicellular response to CNS damage and disease. | Q38181737 | ||
| Preparing the ground for tissue regeneration: from mechanism to therapy | Q38237617 | ||
| Macrophages and therapeutic resistance in cancer | Q38413720 | ||
| TNF Counterbalances the Emergence of M2 Tumor Macrophages | Q38835677 | ||
| Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations | Q39338784 | ||
| Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. | Q39972447 | ||
| mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma | Q40407116 | ||
| A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging | Q40579830 | ||
| New insights into the multidimensional concept of macrophage ontogeny, activation and function. | Q40866271 | ||
| Prognostic and predictive factors in breast cancer by immunohistochemical analysis. | Q40866567 | ||
| The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses | Q41779891 | ||
| Modeling Adult Gliomas Using RCAS/t-va Technology | Q41843698 | ||
| SwissRegulon: a database of genome-wide annotations of regulatory sites | Q42288189 | ||
| Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis | Q42827324 | ||
| P4510 | describes a project that uses | ggplot2 | Q326489 |
| limma | Q112236343 | ||
| P433 | issue | 6288 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | aad3018 | |
| P577 | publication date | 2016-05-01 | |
| P1433 | published in | Science | Q192864 |
| P1476 | title | The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas | |
| P478 | volume | 352 |
| Q47307094 | A NF-κB signature predicts low-grade glioma prognosis: a precision medicine approach based on patient-derived stem cells. |
| Q37580120 | A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer |
| Q48652546 | A drug development perspective on targeting tumor-associated myeloid cells |
| Q38433922 | A novel serum microRNA-based identification and classification biomarker of human glioma |
| Q90376685 | Absence of host NF-κB p50 induces murine glioblastoma tumor regression, increases survival, and decreases T-cell induction of tumor-associated macrophage M2 polarization |
| Q48259319 | Absence of myeloid Klf4 reduces prostate cancer growth with pro-atherosclerotic activation of tumor myeloid cells and infiltration of CD8 T cells. |
| Q89107815 | Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP Proteins |
| Q89823519 | Adoptive Cell Therapy: A Novel and Potential Immunotherapy for Glioblastoma |
| Q33684013 | Associations between prediagnostic blood glucose levels, diabetes, and glioma. |
| Q90058737 | Astrocytes enhance glioblastoma growth |
| Q53099163 | Beyond the M-CSF receptor - novel therapeutic targets in tumor-associated macrophages. |
| Q49723815 | Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer. |
| Q52571424 | Brain-Resident Microglia and Blood-Borne Macrophages Orchestrate Central Nervous System Inflammation in Neurodegenerative Disorders and Brain Cancer. |
| Q90295588 | Buparlisib is a brain penetrable pan-PI3K inhibitor |
| Q47168980 | CSF-1R regulates non-small cell lung cancer cells dissemination through Wnt3a signaling |
| Q101410017 | CSF1R inhibition depletes tumor-associated macrophages and attenuates tumor progression in a mouse sonic Hedgehog-Medulloblastoma model |
| Q55381087 | CSF1R-dependent myeloid cells are required for NK‑mediated control of metastasis. |
| Q60938527 | Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma |
| Q33779328 | Ccl5 establishes an autocrine high-grade glioma growth regulatory circuit critical for mesenchymal glioblastoma survival. |
| Q96110296 | Cellular and Molecular Changes of Brain Metastases-Associated Myeloid Cells during Disease Progression and Therapeutic Response |
| Q57173826 | Challenges in the Treatment of Glioblastoma: Multisystem Mechanisms of Therapeutic Resistance |
| Q92369142 | Characterization of transcriptome profile and clinical features of a novel immunotherapy target CD204 in diffuse glioma |
| Q37660216 | Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors |
| Q92859353 | Chromatin landscapes reveal developmentally encoded transcriptional states that define human glioblastoma |
| Q39168810 | Class (I) Phosphoinositide 3-Kinases in the Tumor Microenvironment |
| Q88386698 | Colony stimulating factor 1 receptor blockade improves the efficacy of chemotherapy against human neuroblastoma in the absence of T lymphocytes |
| Q57152990 | Colony stimulating factor-1 receptor as a treatment for cognitive deficits postfractionated whole-brain irradiation |
| Q33912938 | Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy |
| Q91816037 | Combing the Cancer Genome for Novel Kinase Drivers and New Therapeutic Targets |
| Q57493685 | Comparative proteomic analysis of cat eye syndrome critical region protein 1- function in tumor-associated macrophages and immune response regulation of glial tumors |
| Q89013994 | Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy |
| Q92955884 | Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39 |
| Q55456670 | Copy number profiling across glioblastoma populations has implications for clinical trial design. |
| Q47851037 | Cross-species transcriptional analysis reveals conserved and host-specific neoplastic processes in mammalian glioma. |
| Q42010694 | Crosstalk between glial and glioblastoma cells triggers the "go-or-grow" phenotype of tumor cells. |
| Q92257920 | Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses |
| Q55457323 | Current state of immunotherapy for glioblastoma. |
| Q91594396 | Dissecting intratumoral myeloid cell plasticity by single cell RNA-seq |
| Q55317796 | Editorial: Immunotherapy for Tumor in the Brain: Insights From-and For-Other Tumor Sites. |
| Q52668254 | Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma. |
| Q33837257 | Exosomes from Melatonin Treated Hepatocellularcarcinoma Cells Alter the Immunosupression Status through STAT3 Pathway in Macrophages |
| Q59337420 | Expression of neuropilin-1 is linked to glioma associated microglia and macrophages and correlates with unfavorable prognosis in high grade gliomas |
| Q39343374 | Gastric adenocarcinoma. |
| Q93086679 | Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers |
| Q96576764 | GlioM&M: Web-based tool for studying circulating and infiltrating monocytes and macrophages in glioma |
| Q90926971 | Glioblastoma Therapy in the Age of Molecular Medicine |
| Q92500797 | Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer |
| Q39196377 | Glioblastoma-associated microglia and macrophages: targets for therapies to improve prognosis. |
| Q47879278 | Glioma-induced SIRT1-dependent activation of hMOF histone H4 lysine 16 acetyltransferase in microglia promotes a tumor supporting phenotype |
| Q64963902 | Harnessing Microglia and Macrophages for the Treatment of Glioblastoma. |
| Q30838654 | Heterogeneity of macrophage infiltration and therapeutic response in lung carcinoma revealed by 3D organ imaging |
| Q94006521 | Highlights from the Literature |
| Q91805595 | How cancers usurp macrophages to keep growing |
| Q39144794 | Human Tumor-Infiltrating Myeloid Cells: Phenotypic and Functional Diversity |
| Q89907531 | IFI30 Is a Novel Immune-Related Target with Predicting Value of Prognosis and Treatment Response in Glioblastoma |
| Q91722534 | IGF-1-enhanced miR-513a-5p signaling desensitizes glioma cells to temozolomide by targeting the NEDD4L-inhibited Wnt/β-catenin pathway |
| Q39003387 | Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. |
| Q47915209 | Immunotherapies for malignant glioma. |
| Q52683991 | Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review). |
| Q58605128 | Increased invasive phenotype of CSF-1R expression in glioma cells via the ERK1/2 signaling pathway |
| Q43290383 | Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas. |
| Q38641329 | Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies |
| Q60300784 | Integrin CD11b activation drives anti-tumor innate immunity |
| Q89529262 | Integrin Signaling in Glioma Pathogenesis: From Biology to Therapy |
| Q38838354 | Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma |
| Q52653219 | Kinase inhibitors: the road ahead. |
| Q33744534 | Macrophage Ontogeny Underlies Differences in Tumor-Specific Education in Brain Malignancies |
| Q57816590 | Macrophages and Fibroblasts, Key Players in Cancer Chemoresistance |
| Q37624909 | Macrophages as Key Drivers of Cancer Progression and Metastasis. |
| Q91341263 | Macrophages as regulators of tumour immunity and immunotherapy |
| Q90453024 | Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF-κB signaling |
| Q47773621 | Major Challenges and Potential Microenvironment-Targeted Therapies in Glioblastoma. |
| Q47660509 | Mathematical modeling and computational prediction of cancer drug resistance |
| Q92267431 | Mechanisms of immunotherapy resistance: lessons from glioblastoma |
| Q52765904 | MerTK as a therapeutic target in glioblastoma. |
| Q97643695 | Meteorin-like facilitates skeletal muscle repair through a Stat3/IGF-1 mechanism |
| Q90352618 | Methotrexate Chemotherapy Induces Persistent Tri-glial Dysregulation that Underlies Chemotherapy-Related Cognitive Impairment |
| Q97543222 | MicroRNA-93 acts as an "anti-inflammatory tumor suppressor" in glioblastoma |
| Q58121730 | Microglia Induce PDGFRB Expression in Glioma Cells to Enhance Their Migratory Capacity |
| Q61805378 | Microglia are an essential component of the neuroprotective scar that forms after spinal cord injury |
| Q61451761 | Microglia are effector cells of CD47-SIRPα antiphagocytic axis disruption against glioblastoma |
| Q58801546 | Microglia/Astrocytes-Glioblastoma Crosstalk: Crucial Molecular Mechanisms and Microenvironmental Factors |
| Q89613162 | Models for Monocytic Cells in the Tumor Microenvironment |
| Q39022841 | Molecular Pathways: Deciphering Mechanisms of Resistance to Macrophage-Targeted Therapies |
| Q91676497 | Monocyte heterogeneity and functions in cancer |
| Q64053704 | Multicellular gene network analysis identifies a macrophage-related gene signature predictive of therapeutic response and prognosis of gliomas |
| Q89472896 | Multidimensional communication in the microenvirons of glioblastoma |
| Q90147865 | Myeloid-Derived Suppressive Cells Promote B cell-Mediated Immunosuppression via Transfer of PD-L1 in Glioblastoma |
| Q92660089 | NF-κB p50-deficient immature myeloid cell (p50-IMC) adoptive transfer slows the growth of murine prostate and pancreatic ductal carcinoma |
| Q88669747 | Nanoparticles That Reshape the Tumor Milieu Create a Therapeutic Window for Effective T-cell Therapy in Solid Malignancies |
| Q58576103 | Next-Generation Modeling of Human Cancers |
| Q55456543 | Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma. |
| Q50249667 | Nonresolving macrophage-mediated inflammation in malignancy. |
| Q55285476 | Oligodendrocyte Progenitor Cells and Macrophages/Microglia Produce Glioma Stem Cell Niches at the Tumor Border. |
| Q39267549 | Progress in tumor-associated macrophage (TAM)-targeted therapeutics |
| Q39198154 | Prospects for combining targeted and conventional cancer therapy with immunotherapy |
| Q57798069 | RNA-seq for identification of therapeutically targetable determinants of immune activation in human glioblastoma |
| Q58099090 | Radiogenomics Profiling for Glioblastoma-related Immune Cells Reveals CD49d Expression Correlation with MRI parameters and Prognosis |
| Q92259805 | Resolution of Gastric Cancer-Promoting Inflammation: A Novel Strategy for Anti-cancer Therapy |
| Q64903280 | Single-cell transcriptome analysis of lineage diversity in high-grade glioma. |
| Q60049874 | Specific clinical and immune features of CD68 in glioma via 1,024 samples |
| Q90417081 | T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment |
| Q33664499 | Taming immune suppressor: application of myeloid-derived suppressor cells in anti-cancer gene therapy |
| Q61448757 | Targeting Innate Immunity to Enhance the Efficacy of Radiation Therapy |
| Q92511358 | Targeting Myeloid Cells in Combination Treatments for Glioma and Other Tumors |
| Q33588532 | Targeting colony stimulating factor 1 receptor to prevent cognitive deficits induced by fractionated whole-brain irradiation |
| Q58547311 | Targeting macrophages: therapeutic approaches in cancer |
| Q28066522 | Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type |
| Q39178065 | The Microenvironmental Landscape of Brain Tumors |
| Q38877313 | The Promise of Targeting Macrophages in Cancer Therapy |
| Q89587165 | The Sociobiology of Brain Tumors |
| Q89507027 | The metabolic axis of macrophage and immune cell polarization |
| Q38699394 | The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models. |
| Q90028589 | The role of long non-coding RNAs in mediating chemoresistance by modulating autophagy in cancer |
| Q98725916 | The updated landscape of tumor microenvironment and drug repurposing |
| Q92642332 | Therapeutic Targeting of the IGF Axis |
| Q92461127 | Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response |
| Q91696491 | Toward Normalization of the Tumor Microenvironment for Cancer Therapy |
| Q49544289 | Tumor Associated Macrophages as Therapeutic Targets for Breast Cancer |
| Q46410671 | Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. |
| Q53101640 | Tumor Microenvironment in Treatment of Glioma. |
| Q64261371 | Tumor cells induce LAMP2a expression in tumor-associated macrophage for cancer progression |
| Q47388067 | Tumor suppressive role of miR-194-5p in glioblastoma multiforme |
| Q39100693 | Tumour-associated macrophages as treatment targets in oncology. |
| Q37702186 | Type I insulin-like growth factor receptor signaling in hematological malignancies |
| Q55396890 | Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment. |
| Q90705181 | Understanding the Origin and Diversity of Macrophages to Tailor Their Targeting in Solid Cancers |
| Q89514550 | Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies |
| Q50327117 | Utility of Glioblastoma Patient-Derived Orthotopic Xenografts in Drug Discovery and Personalized Therapy. |
| Q61808064 | Vascular-endothelial response to IDH1 mutant fibrosarcoma secretome and metabolite: implications on cancer microenvironment |
| Q47826206 | When Immune Cells Turn Bad-Tumor-Associated Microglia/Macrophages in Glioma. |
| Q91965847 | [Role of STAT3 in Resistance of Non-small Cell Lung Cancer] |
| Q89017792 | miR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma |
| Q55434830 | miR-130a and miR-145 reprogram Gr-1+CD11b+ myeloid cells and inhibit tumor metastasis through improved host immunity. |
| Q37468744 | p53 Mutation: Critical Mediator of Therapy Resistance against Tumor Microenvironment |
Search more.